. 2021 Oct 20;64(6):484–495. doi: 10.5468/ogs.21264

Table 1.

The baseline characteristics of patients in the included studies

Study	Country	Recruitment period (weeks)	Group	N	Age (yr)	17OHPC dose	Type of treatment in control group	Period of 17OHPC use (weeks)	Cervical length at enrollment (mm)
Blackwell et al. [16] (2020)	USA	16^0/7 to 20^6/7 weeks	17OHPC	1,130	30.0±5.2	250 mg IM weekly	Placebo	16 to 36	Non-selected
Blackwell et al. [16] (2020)	USA	16^0/7 to 20^6/7 weeks	Control	578	29.2±5.2	250 mg IM weekly	Placebo	16 to 36	Non-selected

Ibrahim et al. [13] (2010)	Egypt	Second trimester (weeks not specified)	17OHPC	25	25.3±4.15	250 mg IM weekly	Placebo	14 to 36	Non-selected
Ibrahim et al. [13] (2010)	Egypt	Second trimester (weeks not specified)	Control	25	25.6±3.85	250 mg IM weekly	Placebo	14 to 36	Non-selected

Jafarpour et al. [17] (2020)	Iran	16^0/7	17OHPC	50	25.4±2.6	250 mg IM weekly	No placebo	16 to 37	>30
Jafarpour et al. [17] (2020)	Iran	16^0/7	Control	50	25.0±2.38	250 mg IM weekly	No placebo	16 to 37	>30

Meis et al. [12] (2003)	USA	16⁺⁰ to 20⁺⁶ weeks	17OHPC	310	26.0±5.6	250 mg IM weekly	Placebo	16 to 36	Non-selected
Meis et al. [12] (2003)	USA	16⁺⁰ to 20⁺⁶ weeks	Control	153	26.5±5.4	250 mg IM weekly	Placebo	16 to 36	Non-selected

Berghella et al. [23] (2010)	USA	16⁺⁰ to 22⁺⁶ weeks	17OHPC	52	26.3±4.5	250 mg IM weekly	No placebo	16 to 36	<25
Berghella et al. [23] (2010)	USA	16⁺⁰ to 22⁺⁶ weeks	Control	100	26.8±5.3	250 mg IM weekly	No placebo	16 to 36	<25

Saghafi et al. [11] (2011)	Iran	16 weeks	17OHPC	50	28.98±5.36	250 mg IM weekly	No placebo	16 to 37	Non-selected
Saghafi et al. [11] (2011)	Iran	16 weeks	Control	50	29.32±5.69	250 mg IM weekly	No placebo	16 to 37	Non-selected

Values are presented as mean±standard deviation unless otherwise indicated.

17OHPC, 17-alpha hydroxyprogesterone caproate; IM, intramuscularly.